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Abstract
Purpose: A possible association between metformin use and the development of prostate cancer (PCa) has been reported.
However, there is limited information on the impact of long-term metformin use on serum prostate-speciﬁc antigen (PSA) levels. We
investigated the association between exposure to metformin and PSA levels among diabetic patients who were not previously
diagnosed with PCa.
Methods: The analytic sample consisted of 1363 US men aged above 40 in the National Health and Nutrition Examination Survey
2007 to 2008 cycle. Men who had previous diagnoses of PCa or prostatitis and men exposed to manipulations that might have
affected PSA levels were excluded. Multivariate logistic regression analyses were used to evaluate the association between PSA
levels and metformin use by adjusting for potential confounders.
Results: The mean PSA level of the overall population was 1.8 (standard deviation=3.1)ng/mL. There were no differences in PSA
levels according to the presence of diabetes (P= .517). Among patients with diabetes, metformin users exhibited signiﬁcantly lower
PSA levels compared with nonmetformin users (odds ratio=0.790; 95% conﬁdence interval 0.666–0.938; P= .007). However, no
signiﬁcant difference was found in PSA levels among men over duration of metformin use when levels were stratiﬁed by either 1 year
or 5 years by Pearson’s coefﬁcient.
Conclusion: A negative association between serum PSA levels and metformin use was observed in patients with diabetes.
Duration of metformin use did not inﬂuence PSA levels. Further studies are warranted to elucidate whether the reduction in PSA level
with metformin truly reﬂects reduced risk of PCa development and progression.
Abbreviations: BMI = body mass index, BP = blood pressure, DBP = diastolic blood pressure, NHANES = National Health and
Nutrition Examination Survey, PCa = prostate cancer, PSA = prostate-speciﬁc antigen, SBP = systolic blood pressure, TC = total
cholesterol.
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11. Introduction
Prostate cancer (PCa) is the most commonly diagnosed non-
cutaneous malignancy and the second leading cause of cancer
death among men in the United States.[1] Diabetes mellitus has
been suggested to increase the risk of several malignancies.
However, decreased risk of PCa has been seen in patients with
diabetes, presumably secondary to a hyperinsulinemic state,
which decreases testosterone levels.[2–4] Another feasible expla-
nation is lower serum prostate-speciﬁc antigen (PSA) levels
among diabetic men, as this would lead to less PCa detected by
PSA elevation-driven biopsies and ultimately delayed diagnosis.
Biguanide metformin, the ﬁrst-line therapy of choice for
diabetes, has been suggested to be useful for preventing and
treating various cancer types through direct and indirect
mechanisms.[5–6] Metformin, an activator of adenosine mono-
phosphate-activated protein kinase, exerts its antineoplastic
effects by inhibiting the mammalian target of rapamycin and,
thus, decreasing cell growth.[5–6] In PCa, metformin reduces the
hyperinsulinemic state, which may indirectly reduce the risk of
PCa development and progression.[7]
Existing studies have evaluated the role of metformin in PCa.[8]
However, results from epidemiological studies are conﬂicting,
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role of metformin underlying PCa development. Several studies
have reported a negative association between PCa and serum
PSA, the most widely used biomarker for PCa risk and
progression.[9] However, it is still not clear whether diabetes
exerts a protective role against PCa or whether long-term use of
metformin itself is related to decreased PSA levels.
We investigated serum PSA levels according to the presence of
diabetes, metformin use, and the duration of metformin use in
patients with diabetes who have not been previously diagnosed
with PCa. To our knowledge, this is the ﬁrst study to utilize the
National Health and Nutrition Examination Survey (NHANES)
2007 to 2008, a large, cross-sectional dataset that is representa-
tive of the US population.2. Materials and methods
2.1. Study population
NHANES is a cross-sectional observational study that collects
health-related information using a multistage probability design
representative of the general noninstitutionalized US population.
The institutional review board of the National Center for Health
Statistics approved the protocol for NHANES, and informed
consent was obtained. This study included data from male
participants aged 40 and older in the 2007 to 2008 cycle.2.2. Measurement and classiﬁcation of variables
SerumPSAconcentrationwasmeasured inmen40years of age and
older who had never been diagnosed with PCa or prostatitis.
Patients who received prostate manipulation, such as prostate
biopsy, surgery, or cystoscopy within 1 month, and rectal
examination within 1 week, were excluded from analysis. Serum
PSA level was measured using the Hybritech method on Beckman
Access (Fullerton, CA). Serum total cholesterol (TC) concentration
was measured enzymatically. All data were retrieved and utilized
from NHANES website (https://wwwn.cdc.gov/nchs/nhanes).
Data for body mass index (BMI) and blood pressure (BP) were
obtained from the examination component of the NHANES.
BMI was calculated as weight in kilograms divided by height in
meters squared. BP was measured using a mercury sphygmoma-
nometer.[10]
Information on the prescribed medication was collected using
self-reported household interviews. Metformin use and durationTable 1
Characteristics of the study population.
Yes
All patients Metformin use No metformin u
(n=1441, 100%) (n=110, 7.6%) (n=130, 9.0%
Age, y 59.2 (12.1) 62.9 (10.1) 63.5 (10.9)
BMI, kg/m2 28.8 (5.5) 31.6 (6.4) 30.6 (6.0)
SBP, mmHg 130.3 (18.9) 129.6 (19.0) 137.4 (21.2)
DBP, mmHg 73.8 (13.1) 68.2 (13.8) 71.1 (15.4)
TC, mg/dL 197.6 (42.1) 180.0 (46.1) 177.2 (41.5)
PSA, ng/mL 1.8 (3.1) 1.3 (1.2) 2.0 (2.2)
Data are shown as mean (standard deviation).
BMI=body mass index, DBP=diastolic blood pressure, PSA=prostate-speciﬁc antigen, SBP= systolic
∗
P value calculated using t test.
† P value calculated using logistic regression for multivariate analysis.
2of use were obtained using standardized generic prescription drug
codes.2.3. Statistical analysis
Data are reported as means (standard deviation) for continuous
variables and as percentages for categorical variables. For
univariate analysis, the t-test was used to compare continuous
variables. Multivariate analysis used multivariate models of
logistic regression including all risk factors that were signiﬁcantly
associated in the univariate analysis. Determination for the
presence of statistically signiﬁcant correlative relationships was
conducted by using Pearson’s coefﬁcients (R).
SPSS software version 23.0 (SPSS Inc., Chicago, IL) was used
for statistical analyses, and all statistical tests were 2-tailed. A
P value of <.05 was considered statistically signiﬁcant.3. Results
3.1. Characteristics of the study population
Baseline characteristics of the study population are shown in
Table 1. Among 1441 participants, 240 (16.7%) patients had
diabetes. Among these patients, 110 (45.8%) patients were on
metformin. BMI, systolic blood pressure (SBP), and TC were
signiﬁcantly higher in patients with diabetes both in univariate
and multivariate analyses. However, diastolic blood pressure
(DBP) was signiﬁcantly higher in the nondiabetic group.3.2. Serum PSA levels
There were no signiﬁcant differences in serum PSA levels between
the diabetic group and the nondiabetic group (P= .517). Among
patients with diabetes, patients on metformin had signiﬁcantly
lower PSA levels (P= .007) and SBP (P= .005) than those who
were not on metformin (Table 1). The PSA level of patients with
diabetes on metformin was on average 34% lower than that of
patients with diabetes and not on metformin.
PSA levels were also compared according to the duration of
metformin use. There were no differences in PSA levels by
duration of metformin use when stratiﬁed by either 1 year
(Table 2) or 5 years (Table 3). Two-way scatter plot evaluation
for PSA levels and duration of metformin use showed weak
negative relationship (Fig. 1), with Pearson’s correlation
coefﬁcient of 0.119 which was not signiﬁcant (P= .217).Diabetes
No
se
) P
∗
P† (n=1201, 83.3%) P
∗
P†
.687 58.3 (12.3) <.001 .053
.209 28.3 (5.2) <.001 <.001
.003 .005 129.6 (18.5) .001 .001
.127 74.6 (12.6) <.001 .001
.624 201.4 (40.7) <.001 <.001
.002 .007 1.9 (3.3) .517
blood pressure, TC= total cholesterol.
Figure 1. Pearson correlation scatter plot of PSA levels and duration of
metformin use. PSA = prostate-speciﬁc antigen.
Table 2
Characteristics of patients with diabetes according to duration of
metformin use by 1 year.
Metformin use <1 year Metformin use ≥1 year
(n=12) (n=98) P
∗
Age, y 57.9 (11.4) 63.5 (9.8) .069
BMI, kg/m2 28.4 (6.5) 32.0 (6.4) .072
SBP, mmHg 127.3 (14.9) 129.9 (19.5) .666
DBP, mmHg 70.3 (11.9) 67.9 (14.0) .572
TC, mg/dL 175.8 (33.4) 180.5 (47.5) .745
PSA, ng/mL 1.0 (1.2) 1.4 (1.2) .287
Data are shown as mean (standard deviation).
BMI=body mass index, DBP=diastolic blood pressure, PSA=prostate-speciﬁc antigen, SBP=
systolic blood pressure, TC= total cholesterol.
∗
P value calculated using t test.
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It is unclear whether diabetes itself exerts a protective role against
PCa or whether the use of metformin is related to decreased PSA
levels. After adjusting for confounders, PSA level was signiﬁcant-
ly and independently associated with metformin use in diabetic
men, and diabetes itself was not a factor for lower serum PSA
levels. Moreover, the duration of metformin use did not inﬂuence
PSA levels. To the best of our knowledge, this is the ﬁrst study to
utilize the NHANES registry to compare differences in PSA levels
according to metformin use and duration of use in patients who
have not been previously diagnosed with PCa.
Our results compare favorably with several studies in the
literature that compared serum PSA levels in diabetic men.
Haring et al evaluated PCa incidence among users of metformin
and other antidiabetic drugs in the Finnish Randomized Study of
Screening for PCa.[11] In their study, patients on antidiabetic
drugs exhibited lower PSA levels compared to nonusers.[11]
However, the effect of metformin on PSA levels was not
separately evaluated.Moreover, patients on drugs that may affect
PSA levels, namely 5a-reductase inhibitors or nonsteroidal or
anti-inﬂammatory drugs were not excluded from analysis.
Jayalath et al[9] reported a relationship between metformin use
and serum PSA levels in which mean PSA levels were 30% lower
in metformin users, similar to our observation. In addition, an
inverse dose–response relationship was observed. In vitro studies
have reported that metformin treatment reduces PSA gene
expression and cancer cell viability, a possible explanation of our
results.[12–15] To date, no existing literature has reported thatTable 3
Characteristics of patients with diabetes according to duration of
metformin use by 5 years.
Metformin use <5 year Metformin use ≥5 year
(n=57) (n=53) P
∗
Age, y 61.3 (10.8) 64.7 (9.0) .074
BMI, kg/m2 31.8 (6.6) 31.4 (6.3) .736
SBP, mmHg 126.1 (16.5) 133.3 (20.8) .046
DBP, mmHg 67.5 (15.3) 68.9 (12.0) .607
TC, mg/dL 179.9 (44.0) 180.0 (48.7) .994
PSA, ng/mL 1.4 (1.3) 1.3 (1.1) .840
Data are shown as mean (standard deviation).
BMI=body mass index, DBP=diastolic blood pressure, PSA=prostate-speciﬁc antigen, SBP=
systolic blood pressure, TC= total cholesterol.
∗
P value calculated using t test.
3metformin increases PSA levels, which would contradict our
observation.
A noteworthy ﬁnding in our study was that there was no
signiﬁcant difference in PSA levels between patients with and
without diabetes. On the contrary, several studies have reported
an inverse relationship between diabetes and overall risk of
PCa.[16–17] A general hypothesis is that the hyperinsulinemic state
of diabetes decreases testosterone levels, which may reduce the
risk of PCa.[2–4] However, not all study results are consistent, and
studies have reported a high prevalence of high-grade cancers
in diabetic men.[18–19] Although the pathophysiology is incom-
pletely understood, a possible explanation is that insufﬁcient
testosterone affects the prostate proliferation cycle and promotes
abnormal epithelial differentiation, stimulating cancer cells to
dedifferentiate to more aggressive tumors.[20]
In contrast, studies have reported that diabetes may increase
the risks of several cancers such as pancreatic cancer, liver cancer,
breast cancer, and colorectal cancer.[21] This result could be
explained by reduced insulin sensitivity with compensatory
hyperinsulinemia and elevated levels of insulin-like growth
factors, which may in turn stimulate cell proliferation in the
liver, pancreas, colon, ovary, breast, and prostate.[21] These 2
hypotheses are opposing, and evidence is sparse and inconsistent.
Existing epidemiological studies are also controversial. Bansal
et al[22] reported that diabetes is associated with a reduced risk
of PCa. Conversely, multiple studies including a meta-analysis
strongly support that diabetes is associated with an increased risk
of PCa in Asian men.[23,24] The retrospective nature of these
studies and the immortal time bias along with incomplete
adjustments for confounders support the need of a larger,
prospective study to arrive at a deﬁnite conclusion.
There has been considerable debate regarding whether the use
of metformin use is signiﬁcantly associated with reduced risk of
PCa development. Several meta-analyses demonstrated that
metformin use is associated with decreased incidence of
PCa.[25–26] Although our study did not evaluate the incidence
of PCa due to a limited number of events, we inferred that low
PSA levels may potentially lead to less PSA-driven prostate
biopsies, eventually leading to a lower rate of PCa diagnosis. This
detection bias may have inﬂuenced the results of other studies
that reported a lower incidence of PCa in metformin use groups.
[3] Waters KM, Henderson BE, Stram DO, et al. Association of diabetes
Park et al. Medicine (2017) 96:51 MedicineObesity induces a state of chronic inﬂammation and insulin
resistance, which may ﬁnally lead to diabetes.[27] Our results
conﬁrmed that BMI is signiﬁcantly higher in patients with
diabetes. Furthermore, our results showed that patients with
diabetes had signiﬁcantly higher SBP but lower DBP compared
with patients without diabetes. It is generally reported that
patients with diabetes have a greater incidence of cardiovascular
disease, cerebrovascular disease, and renal disease than the
general population.[28] Contrary to common ﬁndings, our results
showed that DBP was signiﬁcantly lower in patients with
diabetes. Further study on the difference between SBP and DBP in
patients with cardiovascular disease would be illuminating.
Several studies reported that increased metformin use duration
was associated with decreased incidence of PCa. Preston et al
reported that metformin use of less than 1.5 years was not
associated with a risk reduction, but metformin use of more than
or equal to 3 years was associated with a risk reduction compared
with nonusers.[29] Although our study did not evaluate the
association between PCa incidence and duration of metformin
use, we presumed that use of metformin for at least 1 year may
have decreased PSA levels to a minimum level. Future studies
should evaluate whether the prolonged effect of low PSA level
might eventually decrease the incidence of PCa.
This study has several limitations. First, due to the limitations
of its cross-sectional design, a causal relationship cannot be
established. Second, our study endpoint was conﬁned to serum
PSA level, which is an imprecise proxy for PCa risk. Moreover,
the association between metformin use and diagnosis of PCa was
not evaluated due to a limited number of events in our
population. Third, type I and type II diabetes were not
distinguished and separately analyzed. Some studies reported
that type I diabetes, which accounts for 5% to 10% of all
diagnosed diabetes,[30] was not associated with increased risk of
cancer.[31–32] Therefore, the association between PSA levels in
patients with and without diabetes might have been under-
estimated.
Our study showed a signiﬁcant association between metformin
use and PSA levels in patients with diabetes that had not been
previously diagnosed with PCa. Since duration of metformin use
did not signiﬁcantly inﬂuence PSA levels, we infer that after a
minimal use of 1 year, PSA levels do not signiﬁcantly decrease
with metformin use. Moreover, we observed no difference in PSA
levels between patients with and without diabetes. Future studies
conﬁrming the exact role of metformin in the prostate
microenvironment are warranted to conﬁrm the feasibility of
metformin use for preventing and treating PCa.5. Conclusion
A negative association between serum PSA levels and metformin
use was observed in patients with diabetes. Metformin use of
more than 1 year in duration did not inﬂuence PSA levels. Further
studies are warranted to elucidate whether the reduced PSA level
with metformin truly reﬂects reduced risk of disease development
and progression.
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